RossDS, BurchHB, CooperDS, et al.2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid2016;26:1343‐1421; doi: 10.1089/thy.2016.0229.
2.
TörringO, WattT, SjölinG, et al.Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves’ hyperthyroidism: A long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status. Thyroid2019;29(3):322‐331; doi: 10.1089/thy.2018.0315.
3.
FungMHM, LukY, YuenKKW, et al.The two-year results of using radiofrequency ablation as a novel treatment for persistent or relapsed Graves’ disease: A prospective study. Thyroid2024;34(8):1017‐1026; doi: 10.1089/thy.2024.0177.
4.
FungMHM, LiuX, LuiD, et al.Comparing the health-related quality of life at two years after successful treatment of relapsed Graves' disease with radiofrequency ablation, surgery, or radioiodine. World J Surg2025;49(11):3142‐3151; doi: 10.1002/wjs.70035.
5.
MeyerVM, BenjamensS, El MoumniM, et al.Global overview of response rates in patient and health care professional surveys in surgery: A systematic review. Ann Surg2022;275(1):E75‐E81; doi: 10.1097/SLA.0000000000004078.
6.
O’NeillCJ, RoweCW, Morris-BaguleyH, et al.Thyroid cancer survivors experience persistent symptoms and health-related quality-of-life deficits 12 months following surgery. Thyroid2025;35(9):1039‐1051; doi: 10.1089/thy.2025.0149.
